We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Cytotoxic Colchicine Alkaloids: From Plants to Drugs

Joanna Kurek

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.72622>

Abstract

Plants produce and store many organic compounds like amino acids, proteins, carbohydrates, fats, and alkaloids, which are usually treated as secondary metabolites. Many alkaloids are biologically active for humans. For thousand years, extracts from plants containing alkaloids had medicinal use as drugs and they owe their powerful effects thanks to presence of alkaloids. Alkaloids have anti-inflammatory, antibacterial, analgesic, local anesthetic, hypnotic, psychotropic, antimitotic, and antitumor activity. Nowadays, alkaloids from plants are still of great interest to organic chemists, pharmacologists, biologists, biochemists, and pharmacists. Plants of *Liliaceae* family contain colchicine as the main alkaloid, which has cytotoxic activity. Colchicine has limited pharmacological application because of its toxicity, but many derivatives have been synthesized and their cytotoxic activity and tubulin-binding properties have been tested. Many of the synthetic derivatives showed good cytotoxic activity.

Keywords: colchicine, colchinoids, plants containing colchicine alkaloids, cytotoxic compounds, cancer cell lines, cytotoxic activity

1. Introduction

One of the best known biologically active compounds from ancient times is colchicine (**Figure 1**), an alkaloid naturally occurring in *Colchicum autumnale* a plant of *Liliaceae* family and also in *Gloriosa superba*. In the past, extracts from these plants containing colchicine were useful in gout therapy and still are [1]. The anti-gout action of colchicine could be explained by its powerful spindle toxicity [2, 3]. Moreover, colchicine is a useful medicine in the treatment of familial Mediterranean fever (FMF), liver cirrhosis, chronic myelocytic leukemia, Behçet disease, chondrocalcinosis and other microcrystalline arthritis also more recently in cardiovascular diseases, Sweet's syndrome, and hepatic disorders (HCC hepatocellular carcinoma) [4–12].

Figure 1. Colchicine molecule (color version available on the online version).

In 2009, the FDA approved colchicine for the treatment of gout and familial Mediterranean fever (FMF) [1]. Recent investigations utilizing large cohorts of gout patients who have been taking colchicine for years have demonstrated novel applications within oncology, immunology, cardiology, and dermatology [4, 13–16]. Some emerging dermatologic uses include the treatment of epidermolysis bullosa acquisita, leukocytoclastic vasculitis, and aphthous stomatitis. Colchicine has also anti-inflammatory and anticancer properties. Colchicine has been proven to have a fairly narrow range of effectiveness as a chemotherapy agent though it is also occasionally used in veterinary medicine to treat cancers in some animals. Nowadays, colchicine is very useful as an antimitotic agent in cancer research involving cell culture [17]. Colchicine has limited medical usage because of its high toxicity [18]. Because of this reason, many attempts have been made to design, synthesize new colchicine derivative and to screen them as cytotoxic agents to search more biologically active/effective compounds with lower toxicity.

2. Cytotoxic colchinoids in plants

Colchicine **1** and related alkaloids were isolated from many plants of *Liliaceae* family. The *Colchicum* species are most known plants in which colchicine exists in majority and other colchicine-like derivatives are in minority. Unripe seeds of *Colchicum* plants were found to contain 40% less colchicine **1** than fully ripe one [19]. Colchicine occurs in all parts of *Colchicum* plants but especially in seeds and bulbs. One of the most known plants which contain colchicine **1** is meadow saffron (*C. autumnale*, **Figure 2**). The other plants of *Colchicum* sp. are: *C. crocifolium*, *C. turicum*, *C. kesselvingii*, *C. luteum*, *C. byzantinum*, *C. crocifolium*, *C. szovitsii*, *C. soboliferum*, and many more [20]. Beside **1** in these plants of *Colchicum* species also are present: 2-demethylcolchicine **2**, 3-demethylcolchicine **3**, demecolcine **4**, 2-demethylcolchicine **5**, 3-demethylcolchicine **6**, *N*-methyl-demecolcine **7**, 3-demethyl-*N*-methyl-demecolcine **8**, *N*-formyl-*N*-deacetylcolchicine **9** [19], *N*-deacetylcolchicine **10**, *N*-deacetylcolchicine **11**, and colchicine **12**. Many of colchicine alkaloids exist in plants in glycoside form [21, 22]. Colchicine and its derivatives are also present in other plants like: *Gloriosa superba*, *Merendera* species (*M. kurdica*, *M. sobolifera*, *M. vaddeana*, *M. robusta*, and many more), *Bulbocodium vernum*, *Androcymbium palaestinum*, and *Kreysigia multiflora* [20, 23]. In *Gloriosa superba* plants were found

Figure 2. Meadow saffron *Colchicum autumnale*: bulb, flowers, and leaves (color version available on the online version). (*author's own photos).

alkaloids: **1**, **2**, **5**, **6**, 2,3-*O*-didemethylcolchicine **13**, 2,3-*O*-didemethyl-*N*-deacetylcolchicine **14**, and 2,3-*O*-didemethyl-*N*-formyl-*N*-deacetylcolchicine **15** [22]. More recently, a new colchicine glycoside, 3-*O*-demethylcolchicine-3-*O*- α -D-glucopyranoside **41** has been isolated from *Gloriosa superba* seeds [22]. Moreover, in plants extracts were also isolated photolysis products of colchicine like α -lumicolchicine, β -lumicolchicine, γ -lumicolchicine, and their 3-*O*-demethyl derivatives [24, 25].

3. Unusual chemical structure of colchinoids

Colchicine (**1**) is an alkaloid with unusual structure and has the whole family of structural relations. This alkaloid was isolated in 1820 by Pelletier and Caventou [26]. Although listed at this point, colchicines are biogenetically very close to the isoquinoline alkaloids. Colchicines posses exocyclic N-atoms [15]. Corrected structure of colchicine molecule with seven-membered C ring proposed Dewar in 1945 [27]. Colchicine possesses both one stereogenic center at C7 and chirality axis, since the two rings A and C are not positioned in coplanar fashion (atropisomerism). In naturally occurring (–)-aR,7S-colchicine, the two rings (A and C) are oriented in a clockwise manner [15].

4. Natural, semi-synthetic, and synthetic colchicines

Many naturally occurring colchicine alkaloids (some of them are listed in **Figures 3** and **4**) have been converted into semi-synthetic compounds and have been prepared as potential antitumor agents. Usually starting with colchicine **1** hundreds of semi-synthetic and synthetic colchicine derivatives have been synthesized [28–30].

Starting compound was 1,2-*O*-didemethylcolchicine **16** converted into 1,2,3-*O*-tridemethylcolchicine **17** [28–30], 1,2,3-*O*-tridemethyl-*N*-deacetylcolchicine **18** [28–30], 1,2,3-*O*-tridemethyl-*N*-deacetyl-*N*-trifluoroacetylcolchicine **19** [28–30], and 1,2,3-*O*-tridemethyl-*N*-deace

Figure 3. Naturally occurring colchicine derivatives (color version available on the online version).

tyl-*N*-formyl(2,4,6-trihydroxyphenyl)colchicine **20** [28–30]. 1,2-didemethyl-*N*-deacetylcolchicine **21** was converted into: 1,2-didemethyl-*N*-deacetyl-*N*-(propane-2,3-diol)colchicine **22** [31] and 1,2-didemethyl-*N*-deacetyl-*N*-(propane-2,3-diacetyl)colchicine **23** [31]. Derivatives **24** with halogene substituent and with alkyl, aryl, or hydrogen **25** at C-10 position have also been obtained [32]. 10-demethoxy-10-azido-colchicine **26** [33] and 10-demethoxy-10-amino-colchicine = colchiceinamide **27** [34]. 2-Demethyl-*N*-benzylidemecolchicine = speciocolchicine **28** [35] has been prepared from 2-demethyldemecolchicine. 10-*O*-*p*-tosylsulfonylcolchicine **29** can be converted into compound **24** [36]. One of the interesting derivatives modified at C-7 position by –sulfur-containing substituent is *N*-deacetyl-*N*-(2merkaptoacetyl)-colchicine **30** (DAM-colchicine) [37]. Glycopeptide dendrimer conjugates of colchicine modified at C-7 have been synthesized and tested as mitosis inhibitors [38]. *N*-substituted derivatives colchicine-lipids with different length of alkyl chain of olenyl and stearyl groups have been obtained and their interaction with lipid membrane has been studied [39]. Ring-C-modified colchicine analogs with different nitroso substituents in Diels-Alder reaction have been obtained [40]. 3-Demethyl derivative of colchicine and 10-methylthiocolchicine have been obtained also by regioselective bioconversion of **1** and **31** by microorganisms *Bacillus* IND-B 375 and stain of *Bacillus megaterium* ACBT03 [41, 42].

Figure 4. Natural, seminatural and synthetic colchicines (chosen examples).

4.1. C-10 sulfur-containing derivatives

After many years of searching colchicine derivatives as good cytotoxic agents, it was established that exchange of methoxyl substituent $-\text{OCH}_3$ at C-10 position to amino group (NH_2 , NHR_1 , or NR_1R_2) and especially to methylthio ($\text{CH}_3\text{S}-$) or alkylthio increases cytotoxic activity. Thiocolchicine **31** is a colchicine **1** derivative used in the therapy of some diseases [43] and extensively studied in the field of oncological research as antimitotic agent [44–46]. There were mentioned some of wide range of synthesized colchicine compounds with thio substituent at C-10 position during last 60 years. Derivatives with alkylthio substituent at C-10 position have been synthesized from colchicine **31–35** (Figure 5) [47]. *N*-deacetyl-10-methylthiocolchicine **36** was converted into compounds: **37** [44], **38** and **39** [44]. 10-Methylthiocolchicine was modified at C-3 position to compound 3-demethoxy-3-amino-10-methylthiocolchicine **40** and then to 3-demethoxy-3-glycosylaminothiocolchicines **41–47** (Figure 5) [48]. From derivatives **48–52**

- 31** $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{COCH}_3$
32 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{C}_2\text{H}_5$,
 $\text{R}_4 = \text{COCH}_3$
33 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = n\text{C}_3\text{H}_7$,
 $\text{R}_4 = \text{COCH}_3$
34 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = i\text{C}_3\text{H}_7$,
 $\text{R}_4 = \text{COCH}_3$
35 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = n\text{C}_4\text{H}_9$,
 $\text{R}_4 = \text{COCH}_3$
36 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{H}$
37 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{CO}(\text{CH}_2)_n\text{CH}_3$, $n=0-8$
38 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{CO}(\text{Ph or Ar})$
39 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OH}$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{CH}_2\text{C}_6\text{H}_4\text{-}p\text{NO}_2$
40 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{NH}_2$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{COCH}_3$
41 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{COCH}_3$, $\text{R}_3 = D\text{-glucopyranosyl}$,
42 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{COCH}_3$, $\text{R}_3 = D\text{-arabinopyranosyl}$,
43 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$,
 $\text{R}_3 = D\text{-lyxopyranosyl}$,
44 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = D\text{-xylopyranosyl}$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
45 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$,
 $\text{R}_3 = L\text{-rhamnopyranosyl}$
46 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = D\text{-manopyranosyl}$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$

- 47** $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = L\text{-fucopyranosyl}$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
48 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{OH}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
49 $\text{R}_1 = \text{R}_3 = \text{OH}$, $\text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
50 $\text{R}_1 = \text{OCH}_3$, $\text{R}_2 = \text{R}_3 = \text{OH}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
51 $\text{R}_1 = \text{R}_3 = \text{OCH}_3$, $\text{R}_2 = \text{OH}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
52 $\text{R}_1 = \text{R}_2 = \text{OH}$, $\text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
53 $\text{R}_1 = \text{R}_3 = \text{Ac}$, $\text{R}_2 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
54 $\text{R}_1 = \text{OCH}_3$, $\text{R}_2 = \text{R}_3 = \text{Ac}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
55 $\text{R}_1 = \text{R}_3 = \text{OCH}_3$, $\text{R}_2 = \text{Ac}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
56 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{Ac}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
57 $\text{R}_1 = \text{R}_2 = \text{Bz}$, $\text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
58 $\text{R}_1 = \text{OH}$, $\text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
59 $\text{R}_1 = \text{R}_3 = \text{OCH}_3$, $\text{R}_2 = \text{OH}$, $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
62 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{OCH}_2\text{CH}(\text{OH})\text{CH}_2\text{OH}$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
63 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{OCH}_2\text{CH}(\text{OH})\text{CH}_2\text{NH}_2$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
64 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{OCH}_2\text{CO}_2\text{H}$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 = \text{COCH}_3$
65 $\text{R}_1 = \text{R}_2 = \text{OCH}_3$, $\text{R}_3 = \text{OCH}_2\text{CH}(\text{Cl})\text{CH}_2\text{OH}$,
 $\text{R}_5 = \text{CH}_3$, $\text{R}_4 = \text{COCH}_3$
66 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 =$
67 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 =$
68 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_4 =$
69 $\text{R}_1 = \text{R}_3 = \text{OCH}_3$, $\text{R}_4 = \text{COCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_2 = -\text{OCOCH}_2\text{NCH}_3$
70 $\text{R}_1 = \text{R}_3 = \text{OCH}_3$, $\text{R}_4 = \text{COCH}_3$, $\text{R}_5 = \text{CH}_3$,
 $\text{R}_2 = -\text{OCOCH}_2\text{NCH}_3 \cdot L\text{-tartarate}$
71 $\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{OCOCH}_3$, $\text{R}_5 = \text{SCH}_3$,
 $\text{R} = \text{COC}_6\text{H}_4\text{-}p\text{NO}_2$

Figure 5. Seminatural and synthetic thiocolchicines (chosen examples).

esters of 1-*O*-demethyl, 2-*O*-demethyl and 3-*O*-demethylthiocolchicine were also obtained **53–57** (**Figure 5**) [49]. 10-methylthiocolchicine has been demethylated to 1-demethyl-10-methylthiocolchicine **58**, 2-demethyl-10-methylthiocolchicine **59**, and 1,2-*O*-didemethylthiocolchicine **52** then **58** and **59** have been oxidized to quinine (**Figure 6**) [50]. Complex ethers of 3-demethyl-10-methylthiocolchicine **62–65** have been prepared as potential pharmaceuticals [51]. The C-7 amide group of ring B with (*R*)-configuration [15] is also one of the crucial factors which decide of molecule's anticancer activity. Eight synthetic derivatives of *N*-deacetylthiocolchicine have been obtained and tested against cancer cell lines and 3 of them showed good activity **66**, **67**, **68** [52]. Thiocolchicine derivative **69** has been modified at C-2 carbon atom and then converted into salt **70** [53]. Among 37 thiocolchicine derivatives tested, compound **71** showed good activity as inhibitor of topoisomerases *in vitro* [54]. *N*-substituted thiocolchicine derivatives and their water-soluble phosphate salts **72–78** (and 5 others) have been obtained and their activity have been tested against cancer cell lines [55] (**Figure 7**).

Figure 6. Thiocolchicines with modified ring A: **60** 1,4-quinone and **61** quinomethane.

Figure 7. Thiocolchicines modified on ring B.

From compound **79** acetamido $-\text{NHCOCH}_3$ substituent from C-7 has been removed and replaced by $=\text{CH}_2$ group [56]. Hybrids of vindoline, anhydrovinblastine, and vinorelbine with thiocolchicine **31** podophyllotoxin and baccatinIII have been tested in arresting cell cycle and cytotoxic activity [57]. Series of thiocolchicine-podophyllotoxin conjugates have been obtained and their tubulin activity has been tested [58].

Compounds **80**, **81**, **82**, **83**, **84**, and **85** have been synthesized by four synthesis steps from colchicine **1** to thiocolchicine **31** then to 7-deacetylthiocolchicine **36** which has been converted into **80** and then to **81**, **82**, **83**, **84**, **85** and eight others which possess six-membered ring B [59].

5. Bioactivity of colchicine and its derivatives

Colchicine **1** has been known and used from ancient times, despite its toxicity to cure acute gout attacks because of its anti-inflammatory properties. After administration of colchicine **1**, it is mainly metabolized in liver *via* demethylation by cytochrome P450 system (isoform CYP 3A4) to 2-demethylcolchicine **2** and 3-demethylcolchicine **3** [11]. Colchicine **12** was described as a metabolite in rats produced by cytochrome P450 3A4 isoform [60], but it does not occur in humans *in vivo* [61]. Colchicine's most common toxicity is gastrointestinal (nausea, vomiting, diarrhea, abdominal pain) which occurs during first 24 hours after overdose. Toxic effect of colchicine appears after oral administration of 7–60 mg of colchicine and is fatal, symptoms occur in about 4 h and death in about 4 days. Severe colchicine overdose may be treated with a colchicine-specific antigen-binding immunoglobulin [11].

Beside colchicine **1** has many naturally occurring derivatives many attempts have been made to discover more effective and less toxic analogs by modifying the substituents of its basic structure.

Colchicine blocks mitosis metaphase due to different anti-mitotic effects: disruption of mitotic spindle formation and second disruption of the sol-gel formation. Colchicine can also interact with lipid membranes. The interaction between colchicine and membrane results with significant alternations of both the properties of the lipid membrane and alkaloid [39]. Tubulin is an α and β heterodimer initially identified as the cellular colchicine-tubulin protein [10, 62]. Colchicine can interact with human serum albumin, which has been studied by spectroscopic method [63, 64]. Study of colchicine-tubulin complex showed that colchicine binds at the location where it prevents curved tubulin from adopting a straight structure, which inhibits assembly. Microtubules are cytoskeletal polymers of tubulin involved in many cellular functions [65]. Their dynamic instability is controlled by many proteins and compounds such as colchicine.

Colchicine and its biologically active derivatives, especially thiocolchicine and its derivatives, have been extensively tested on cancer cell lines for *in vitro* cytotoxicity, in mice, evaluated for inhibition of tubulin polymerization [66], on axonal cytoskeleton of rat peroneus nerve [67]. Thiocolchicine has been studied as a potent compound to treat Peyronie's disease [68]. Derivatives of thiocolchicine have been tested *ex vivo* to human T-lymphoblastoid (CEM) cells [69].

6. Cytotoxic activity of colchicine and its derivatives

Cytotoxic activity of colchicine has been known for many decades. In 1968, it was known that colchicine can efficiently bind to tubulin. Its antitumor activity derives from its tubulin binding activity [39]. Nowadays, it is known that colchicine can act with α and β tubulin in microtubules and disrupt the formation of microtubules. In past decades, many attempts have been made to design and synthesize new colchicine derivatives which could be less toxic and more effective compounds than colchicine as cytotoxic agents. On the basis of years of screening colchicine derivatives, their activity against human cancer cell lines structure: activity relationship has been established. It was found out that derivatives with alkylthio substituents at C-10 position and modified at C-7 usually are more active and less toxic than colchicine. One of the most known active semi-synthetic colchicine derivatives is thiocolchicine (10-methylthiocolchicine) **31**. Some of the obtained derivatives seem to be effective and promising agents against selected human cancer cell lines and possibly in the future could be used as anticancer drugs. Cytotoxic activity of colchicine derivatives has been tested in *in vitro* experiments on mice (KLN205, A2C12, yB8, yD12, β D10, yA7, yA3, B3, β D5, A2B1, yD1) [70] or hamster (CHO-K1) [45] cancer cell lines and human cancer cell lines such as: MFC-7 human breast adenocarcinoma [40, 45, 47, 54, 71, 72] and MDA-MB-231 [47, 72] human Caucasian breast adenocarcinoma, SK-Br-3 human breast cancer cell line [46], DLD-1 [47] and LOVO [47] human colon adenocarcinoma, HCT-5 colon cancer, HCT-15 colon carcinoma [44, 45], A549 human lung adenocarcinoma [44, 52–55, 57, 58, 70], DMS-114 small lung cell cancer [44], SKOV-3 ovarian cancer [46], OVCAR-3 ovarian carcinoma [44], A2780 human ovarian carcinoma cell line [73], 1A9 human ovarian carcinoma [53], KB human epidermoid carcinoma [46, 53, 57], PC-3 prostate cancer [40], H460 human large cell lung carcinoma [71], SF268 human astrocytoma [71], HTC-8 human ileocecal carcinoma cell [46, 57], DU-145 human prostate carcinoma [46], SKMEL-2 human skin malignant melanoma [46, 54], SKMEL-5 human skin malignant melanoma [44], RXF-631 renal carcinoma [44], SNB-19 CNS carcinoma [44], RPMI-7951 malignant melanoma [56], TE671 human medulloblastoma [56], HepG2 human hepatocyte carcinoma [70], CaCo-2 human colon carcinoma [70], and CAKI-1 kidney carcinoma [54]. As a positive control in cytotoxic tests were used: colchicine, doxorubicin or camptothecin and MTT tests [39, 57] or SRB tests MTS assay [70]. Values of IC_{50} for compounds **1**, **4**, **7**, **8**, **31**, **32**, **33**, **34**, and **35** are given in **Table 1**. Naturally occurring colchicine and other colchicine-like alkaloids were tested against human cancer cell lines and usually showed much better activity than parent compound.

Thiocolchicine **31** showed good activity against A2780 human ovarian carcinoma cell line with value of IC_{50} 1.6 nM [73]. The water-soluble compound **69** (salt of succinic acid of *N,N*-dimethyl-*N*-deacetylthiocolchicine) showed selective activity against HTC-8 0.022 μ g/mL and SK-BR-3 0.012 0.022 μ g/mL cancer cells [46]. The second salt of succinic acid of *N*-deacetylthiocolchicine **72** showed activity against five of tested cancer cell lines 0.001–0.005 μ g/mL (HTC-8, SK-BR-3, A549, DU145, KB) [46].

Thiocolchicine derivative **83** modified at C-7 position showed good cytotoxic activity against A549, RPMI-7951, and TE671 cancer cell lines 0.001 nM/mL [56]. Derivatives **66**, **67**, and **68** showed good cytotoxic activity against A549, SKOV-3, SKMEL-2, HCT-15, and MCF-7 cancer cell lines with IC_{50} values 5.2–29.8 nM [52]. **69** and **70** showed significant activity against

Cell line compound	DLD-1	LoVo	MCF-7	MDA MB-231	H460	SF268
1	43.0 [47]	118.8 [47]	41.3 [47]	25.3 [47]	32 [71]	25 [71]
4	—	—	52 [71]	—	44 [71]	39 [71]
7	—	—	151 [71]	—	165 [71]	354 [71]
8	—	—	2440 [71]	—	3200 [71]	981 [71]
31	4.2 [47]	13.6 [47]	55.5 [47]	81.2 [47]	—	—
32	51.2 [47]	19.5 [47]	56.1 [47]	148.3 [47]	—	—
33	71.8 [47]	56.1 [47]	764.4 [47]	704.2 [47]	—	—
34	177.3 [47]	149.6 [47]	564.2 [47]	1103.8 [47]	—	—
35	316.7 [47]	438.0 [47]	873.6 [47]	1773.3 [47]	—	—
Doxorubicin	510.6 [47]	520.2 [47]	1210.1 [47]	935.5 [47]	—	—
Camptothecin	—	—	0.309 [71]	—	0.024 [71]	0.043 [71]

Table 1. The IC₅₀ values (nM) of compounds tested against cancer cell lines: MCF-7 [47], MDA-MB-231 [47], DLD-1 [47], LoVo [47], H460 [71] and SF268 [71]. Data were obtained from triplicate experiments. Doxorubicin was used as positive control (MTT test) [47].

tumor cell lines: A549, 1A9, and KB with values of IC₅₀ 0.02–0.06 µg/mL [53]. Hybrids of vindoline, anhydrovinblastine, and vinorelbine with thiocolchicine have been tested in arresting cell cycle and against A549 cell lines [57].

Many of tested colchicine derivatives and thiocolchicine derivatives obtained by partial synthesis were assayed measuring mitotic arrest in L1210 murine leukemia cell cultures [70], their binding to tubulin *in vitro*, their antitumor activity against the P388 lymphocytic leukemia screen in mice, and their inhibition of swelling produced in rat paws by injection with uric acid. To measure inhibition in binding different colchicine derivatives to tubulin, many tests have been used *in vitro* and *in vivo*: CD spectra [74], radiolabeled compounds, and cancer cell lines.

The effect on tubulin can be assessed *in vitro* by measuring inhibition of tubulin polymerization [53, 66, 70] and binding of radiolabeled colchicine to tubulin [75]. Significant inhibition in binding to tubulin greater than colchicine **1** was observed with 3-demethylcolchicine (**3**), 10-methylthiocolchicine **31**, and 3-demethyl-10-methylthiocolchicine **48** [76]. Significant inhibition of binding radiolabeled colchicine to purified tubulin was observed with thiocolchicine and 3-demethylthiocolchicine (**Table 2**).

Colchicine showed to be too much toxic to be used as a drug candidate for cancer diseases. Colchicine is much more less toxic than colchicine [77]. Through past decades many derivatives were tested against cancer cell lines to checked their cytotoxic activity and activity *in vitro* to disrupt microtubule network and spindle formation. Binding of colchicine analogs to tubulin measured by competition for labeled colchicine is for **1** 5×10^{-6} , **31** 4×10^{-6} , and **41** $2\text{--}3 \times 10^{-5}$ [76]. Inhibition of tubulin assembly by thiocolchicine derivatives **69** and **70** is IC₅₀ 8.7 µM and IC₅₀ 3.8 µM, respectively [53]. The compounds **72**, **76**, and **77** showed potent inhi-

Inhibitor added	Inhibitor:radiolabeled colchicine (%)	
	1:1	10:1
Non-radiolabeled 1	25	83
2	14	60
3	25	77
31	55	94
48	41	89

Table 2. Inhibition [%] of binding radiolabeled colchicine to purified tubulin [76].

bition of tubulin assembly $IC_{50} = 0.8\text{--}1.1\text{ }\mu\text{M}$, for comparison for **1** is $1.5\text{ }\mu\text{M}$ [54]. Compound **83** showed good inhibition of tubulin polymerization and inhibition of colchicine binding (%), IC_{50} $3.4\text{ }\mu\text{M}$ and 60% and **79** IC_{50} $2.4\text{ }\mu\text{M}$ and 91%; **82** IC_{50} $6.6\text{ }\mu\text{M}$ and 78% [56]. Hybrid thiocolchicine-vindoline causes cell cycle arrest in the G2/M phase [57]. Inhibition of tubulin polymerization has been studied with thiocolchicine-podophyllotoxin conjugates, where **31** was modified at C-7 substituent [63].

In vivo P388 mouse leukemia test data P388 for colchicine **1** is 0.5, **31** is 0.18, and **48** is 5 [mg/kg] [76].

7. Pharmacological use of colchinoids

7.1. Colchicine prodrugs

Some of colchicines have been tested as prodrugs. Zyn-linked™ colchicines which are conjugates of colchicine derivatives with proprietary lipophylic molecules (ZYN-160 4-formyl-thiocolchicine, PKH139, PKH153, PKH147) via acid cleavable linkages (PKH155, PKH159, ZYN-217) produced prodrugs (PKH140, PKH154, PKH156, PKH158, ZYN-162) with enhanced antitumor activity (A2780 human ovarian carcinoma cell line) [73]. Conjugates have blocked cell in the G2/M phase of the cell cycle and were up to 100-fold less active *in vitro* than unlinked drug [73]. Ring B-modified colchicine derivative CT20126 showed immunosuppressive and cytotoxic activity [78]. *N*-acetylcolchicinol phosphate is a prodrug (ZD6126) derived from colchicine [79]. Thiocolchicine dimers IDN5404 and IDN5676 have been tested as prodrugs active as inhibitor of Topo-I and without loss of the spindle poison properties [80]. Colchitaxel is another active compound with cytotoxic activity which combines colchicine and paclitaxel [81].

7.2. Drugs with colchicine

Besides antitumor activity, colchicine has anti-inflammatory properties. Colchicine reduces the formation of uric acid crystals in the affected joint and thereby reduces the amount of acute inflammation and pain. It also decreases the levels of uric acid in the blood or the amount that is excreted in the urine. More recently colchicine has been proposed as a potential drug in treatment for various conditions (except gout), what can open new way of its possible future application. Nowadays, colchicine is the useful drug in illnesses: familial Mediterranean fever (FMF),

liver cirrhosis, disk problems, Behçet syndrome, prevention of post-pericardial syndrome, primary biliary cirrhosis, hepatic cirrhosis, dermatitis herpetiformis, Paget's disease of bone, pseudogout, and idiopathic pulmonary fibrosis.

Colchicine can be used to treat familial Mediterranean fever in children 4 years of age and older.

Colchicine is available as a tablet, capsule, and a gel. In tablet form, it is available in a generic 0.6 mg tablet and as Colcrys 0.6 mg tablet. It is available as a capsule in a generic form of 0.6 mg and as Mitigare 0.6 mg capsule. There is a topical gel form of *Colchicum autumnale*, available as ColciGel. Colchicine is commonly administered orally, and use of the topical gel is rare. Due to toxicity of colchicine from 2009, the injectable form is not available. Dosing is dependent on age of patient and kind of illness.

Usually, colchicine is a major component of tablets or capsules in which in a single tablet or capsule its amount is in range of 0.5 or 0.6 mg, sometimes is used as an injection (disk problems). Usually a man/woman of 60 kg takes a dose of 0.5–4.8 mg/day [82, 83]. Since 2008, only oral use of colchicine for patients is possible because of 50 cases of serious adverse events [84]. The known medicines with colchicine are: Colchicum Dispert®, Colcrys, Mitigare, and Colchimax. Col-Benemid or Proben-C is a drug where next to colchicine probenecid is added as uricosuric agent.

7.3. Drugs with colchicine derivatives

One of the known colchicine derivatives that has been used for the treatment of Hodgkin's lymphoma and chronic granulocytic leukemia is *N*-deacetyl-*N*-methylcolchicine, brand name is Colcemid [72]. Moreover, its efficacy against melanoma and prostatic cancer has been established.

Thiocolchicoside (=glucopyranosyl derivative of the semi-synthetic 3-*O*-demethylthiocolchicine 41), is well-known as a muscle relaxing agent and as an anti-inflammatory drug substance [85]. This compound is registered in different countries under the trade names of Colcamyl, Coltramyl, Coltrax, Miorel, and Musco-Ril. Muscle spasm is one of the main factors responsible for chronic pain, and because this particular drug reduces muscle tone, it is used in therapy for the treatment of contractures and inflammatory conditions that affect the muscular system [48].

8. Docking studies

A new tool for searching new potent anticancer agents is docking studies. Some years ago it became possible to study new compounds of possible biological activity by new technical methods like molecular modeling and docking studies [37, 86–90].

9. Conclusion

The way to search new colchicine derivatives especially thiocolchicine derivatives seems to be worth trying because of its promising cytotoxicity. Many new derivatives have been obtained, have been tested for many different cancer cell lines, and many of them seem to be promising anticancer agents in the future.

Scientists still keep designing and synthesizing more and more colchicine derivatives for searching almost ideal anticancer agent. New methods, such as molecular modeling and docking studies, seem to be useful tool in searching for new colchicine derivatives as effective cytotoxic agents.

Conflict of interest

The author declares no conflict of interest.

Author details

Joanna Kurek

Address all correspondence to: joankur@amu.edu.pl

Chemistry Department, Adam Mickiewicz University, Poznań, Poland

References

- [1] Roubille F, Kritikou E, Busseuil D, Barrère-Lemaire S, Tardif J-C. Colchicine: An old wine in a new bottle? *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*. 2013;**12**:1-23. DOI: 10.2174/187152313804998623
- [2] Cook JW, Loudon JD. In: Manske RH. editor. *The Alkaloids*. Vol. 2. New York: Academic Press; 1952. p. 261
- [3] Wildman WC, Pursey BA. In: Manske RH. editor. *The Alkaloids*. Vol. 11. New York: Academic Press; 1962. pp. 41-413
- [4] Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: A meta-analysis. *Cardiovascular Therapeutics*. 2017;**35**(1):10-18. DOI: 10.1111/1755-5922.12226
- [5] Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in pregnancy: A systematic review and meta-analysis. *Rheumatology (Oxford, England)*. 2017;**23**. DOI: 10.10093/rheumatology/kex353
- [6] Wang MX, Deng XL, Mu BY, Cheng YJ, Chen YJ, Wang Q, Huang J, Zhou RW, Huang CB. Effect of colchicine in prevention of pericardial effusion and atrial fibrillation: A meta-analysis. *Internal and Emergency Medicine*. 2016;**11**(6):867-876. DOI: 10.1007/s11739-016-1496-5
- [7] Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. *Heart*. 2016;**102**(8):590-596. DOI: 10.1136/heartjnl-2015-308542

- [8] Agarwal SK, Vallurupalli S, Uretsky BF, Hakeem A. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: An updated meta-analysis of randomized clinical data. *European Heart Journal—Cardiovascular Pharmacotherapy*. 2015;**1**(2):117-125. DOI: 10.1093/ehjcvp/pvv001
- [9] Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, Adler Y. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. *Heart*. 2012;**98**(14):1078-1082. DOI: 10.1136/heartjnl-2011-301306
- [10] Terkeltaub RA. Colchicine update: 2008. *Seminars in Arthritis and Rheumatism*. 2008; **38**:411-419. DOI: 10.1016/j.semarthrit.2008.08.006
- [11] Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. *Annals of the New York Academy of Sciences*. 2009;**1173**:766-773. DOI: 10.1111/j.1749-6632.2009.04674.x
- [12] Smilde BJ, Woudstra L, Fong Hing G, Wouters D, Zeerleder S, Murk JL, van Ham M, Heymans S, Juffermans LJ, van Rossum AC, Niessen HWM, Krijnem PAJ, Emmens RW. Colchicine aggravates coxsackievirus B3 infection in mice. *International Journal of Cardiology*. 2016;**216**:58-65. DOI: 10.1016/j.ijcard.2016.04.144
- [13] Lennerz C, Barman M, Tantawy M, Sopher M, Whittaker P. Colchicine for primary prevention of atrial fibrillation after open-heart surgery: Systematic review and meta-analysis. *International Journal of Cardiology*. 2017;**S0167-5273**(17):32407-32415. DOI: 10.1016/j.ijcard.2017.08.039
- [14] Salih M, Smer A, Charnigo R, Ayan M, Darrat YH, Traina M, Morales GX, DiBiase L, Natale A, Elayi CS. Colchicine for prevention of post-cardiac procedure atrial fibrillation: Meta-analysis of randomized controlled trials. *International Journal of Cardiology*. 2017;**15**(243):258-262. DOI: 10.1016/j.ijcard.2017.04.022
- [15] Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: An ancient drug with novel applications. *The British Journal of Dermatology*. 2017. DOI: 10.1111/bjd.15896
- [16] Puzas IÁ, Álvarez ML, Menendez FÁ, Yuste Romero S, Gómez Prieto O. Wells' syndrome successfully treated with colchicine. *Case Reports in Dermatology*. 2017;**9**:65-69. DOI: 10.1159/000477756
- [17] Cutler SJ, Cutler HG, editors. *Biologically Active Natural Products, Pharmaceuticals*. 2000. p. 84
- [18] Budavari S. *The Merck Index: An Encyclopedia of Chemicals, Drug and Biologicals*. Rahway, New York: Merck&Co.; 1989
- [19] Saxton JE. *The Alkaloids, A Specialist Periodical Report*. vol. 2. London W1V0BN: The Chemical Society Burlington House; 1972. p. 144
- [20] Herbert RB. The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. 2.2. Colchicine. *Natural Product Reports*. 1999;**16**:199-208; Bentley KW. β -Phenylethylamines and the isoquinoline alkaloids. 17. Colchicine and related alkaloids. *Natural Product Reports*. 2002;**19**:332-356; Herbert RB. β -Phenylethylamines and the isoquinoline alkaloids. 3.2. Colchicine. *Natural Product Reports*. 2001;**18**:148-170; Bentley KW.

- β -Phenylethylamines and the isoquinoline alkaloids. 21. Colchicine. Natural Product Reports. 1991;**7**:358-366; Herbert RB. The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. 2.2. Colchicine. Natural Product Reports. 1992;**9**:507-519; Bentley KW. The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. 21. Colchicine and its analogues. Natural Product Reports. 1992;**9**:365-396; Bentley KW. The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. 21. Colchicine and related alkaloids. Natural Product Reports. 1994;**11**:555-576; Bentley KW. The biosynthesis of plant alkaloids and nitrogenous microbial metabolites. 18. Colchicine and related alkaloids. Natural Product Reports. 1995;**12**:419-441
- [21] Saxton JE. The Alkaloids, A Specialist Periodical Report. Vol. 3. London W1V0BN: The Chemical Society Burlington House; 1973. p. 300
- [22] Suri OP, Gupta BD, Suri KA, Sharma AK, Satti NK. A new glycoside, 3-O-demethylcolchicine-3-O- α -D-glucopyranoside, from *Gloriosa Superba* seeds. Natural Product Letters. 2001;**15**(4):217-219. DOI: 10.1080/10575630108041284
- [23] Korner A, Kohn S. Development and optimization of a stability indicating method on a monolithic reversed-phase column for colchicum dry extract. Journal of Chromatography A. 2005;**1089**(1-2):148-157. DOI: 10.1016/j.chroma.2005.06.084
- [24] Chaudhuri PK, Thakur RS. 1,2-Didemethylcolchicine: A new alkaloid from *Gloriosa superba*. Journal of Natural Products. 1993;**56**(7):1174-1176. DOI: 10.1021/np50097a025
- [25] Saxton JE. editor. The alkaloids, A Specialist Periodical Report. Vol. 1. London, W1V0BN : The Chemical Society Burlington House; 1971. p. 457
- [26] Pelletier PJ, Caventou JB. Examen chimique de plusieurs végétaux de la famille des colchicènes, et du principe actif qu'ils renferment. Annales de Chimie Physique. 1820;**14**:69-81
- [27] Dewar MJS. Structure of colchicine. Nature. 1945;**155**:141. DOI: 10.1038/155141d0
- [28] Kashiwara YM, Sun L, Tatematsu H, Bastow KF, Lee KH. Structures of tetra-O-demethylcolchicine, -isocolchicine, and 10-O-demethylcolchicine derivatives. Heterocycles. 1993;**36**:2531-2540. DOI: 10.3987/COM-93-6478
- [29] Bastow KF, Tatematsu H, Sun L, Fukushima Y, Lee KH. Synthesis and biological evaluation of tetrademethyl isocolchicine derivatives as inhibitors of DNA topoisomerase action *in vitro*. Bioorganic & Medicinal Chemistry Letters. 1993;**(3)**:227-234. DOI: 10.1016/S0968-0896(00)82125-2
- [30] Bastow KF, Tatematsu H, Bori ID, Fukushima Y, Lee K-H. Induction of reversible protein-linked DNA breaks in human osteogenic sarcoma cells by novel cytotoxic colchicine derivatives which inhibit DNA topoisomerase II *in vitro*: Absence of cross-resistance in a colchicine-resistant sub-clone. Bioorganic & Medicinal Chemistry Letters. 1993;**3**:1045-1050. DOI: 10.1016/S0960-894X(00)80284-X
- [31] Akyama K. Jpn. Kokai Tokyo. JP 05 38999 (Chem. Abstr., 1994, 120, 245578.). 1993
- [32] Boye O, Hamel E, Brossi A. Medicinal Chemistry Research. 1991;**1**:149-159

- [33] Muzaffar A, Hamel E, Brossi A. Reaction of Colchiceinamide with phosgene and with thiophosgene: Structures and antitubulin activity of tetracyclic oxazolones, oxazothiones and thiazolones of the colchicine series. *Heterocycles*. 1990;**31**(11):2037. DOI: 10.3987/COM-90-5558
- [34] Muzaffar A, Brossi A. Thiocolchicinethiones: Acid hydrolysis of natural and iso-isomers. *Synthetic Communications*. 1990;**6**:713. DOI: 10.1080/00397919008052314
- [35] Muzaffar A, Brossi A, Hamel E. Partial synthesis and antitubulin activity of minor colchicum alkaloids: *N*-acetoacetyl-deacetylcolchicine and 2-demethylspeciosine (Specio-colchine). *Journal of Natural Products*. 1990;**53**(1):1021-1024. DOI: 10.1021/np50070a044
- [36] Cazzava M, Pietra F. A general entry to 10-halocolchicides and 9-haloisocolchicides. *Synthetic Communications*. 1997;**27**(19):3405. DOI: 10.1080/00397919708005641
- [37] Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and stathmine-like domain. *Nature*. 2004;**428**:198-202. DOI: 10.1038/nature02393
- [38] Lagnoux D, Darbre T, Lienhard Schmitz M, Reymond J-L. Inhibition of mitosis by glycopeptide dendrimer conjugates of colchicine. *Chemistry—A European Journal*. 2005;**11**(13):3941-3950. DOI: 10.1002/chem.200401294
- [39] Mons S, Veretout F, Carlier M-F, Erk I, Lepault J, Trudel E, Salesse C, Ducray P, Mioskowski C, Lebeau L. The interaction between lipid derivatives of colchicine and tubulin: Consequence of the interaction of the alkaloid with lipid membrane. *Biochemical Biophysica Acta*. 2000;**1468**:381-396. DOI: 10.1016/S0005-2736(00)00279-0
- [40] Yang B, Zhu ZC, Goodson HV, Miller MJ. Synthesis and biological evaluation of ring-C modified colchicine analogs. *Bioorganic & Medicinal Chemistry Letters*. 2010;**20**:3831-3833. DOI: 10.1016/j.bmcl.1010.03.065
- [41] Poulev A, Bombardelli E, Ponzzone C, Zenk M. Regioselective bioconversion of colchicine and thiocolchicine into their corresponding 3-demethyl derivatives. *Journal of Fermentation and Bioengineering*. 1995;**79**(1):33-38. DOI: 10.1016/0922-338X(95)92740-4
- [42] Dubey KK, Ray AR, Behera BK. Production of demethylated colchicine through microlab transformation and scale-up process development. *Process Biochemistry*. 2008;**43**:252-257. DOI: 10.1016/j.procbio.2007.12.002
- [43] Wolach B, Gotfried M, Jedeikin A. Colchicine analogues: Effect on amyloidogenesis in a murine model in vitro, on polymorphonuclear leukocytes. *European Journal of Clinical Investigation*. 1992;**22**(9):630-634. DOI: 10.1111/j.1365-2362.1992.tb01516.x
- [44] Sun L, Hamel E, Lin CM, Hastie SB, Pyluck A, Lee K-H. Antitumor agent. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: *N*-acyl-, *N*-aroyl- and *N*-(substituted benzyl) deacetylthiocolchicines as a potent cytotoxic and antimitotic compounds. *Journal of Medicinal Chemistry*. 1993;**36**(10):1474-1479. DOI: 10.1021/jm00062a021
- [45] De Vincenzo R, Scambia G, Ferlini C. Antiproliferative activity of colchicine analogues on MDR-positive and MDR negative human cancer cell lines. *Anti-Cancer Drug Design*. 1998;**13**(1):19-33

- [46] De Vincezo R, Ferlini C, Distefano M. Biological evaluation on different human cancer cell lines of novel colchicine analogues. *Oncology Research*. 1999;**11**(3):145-152
- [47] Kurek J, Boczoń W, Murias M, Myszkowski K, Borowiak T, Wolska I. Synthesis of sulfur containing colchicine derivatives and their biological evaluation as cytotoxic agents. *Letters in Drug Design & Discovery*. 2014;**11**(3):279-289. DOI: 10.2174/15701808113106660086
- [48] Gelmi ML, Pocar D, Pontremoli G, Pellegrino S, Bombardelli E, Fontana G, Riva A, Balduini W, Carloni S, Cimino M, Johnson F. Demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle, relaxant compounds. *Journal of Medicinal Chemistry*. 2006;**49**(18):5571-5577. DOI: 10.1021/jm060585t
- [49] Kerekes P, Brossi A. Esters of 1-O-demethylthiocolchicine s: Formation of isomers in chloroform solution. *Helvetica Chimica Acta*. 1985;**68**(3):571-579. DOI: 10.1002/hlca.19850680306
- [50] Guan J, Brossi A, Zhu XK, Wang HK, Lee KH. Oxidation products of phenolic thiocolchicines: Ring a quinones and dienones. *Synthetic Communications*. 1998;**28**:1585-1590. DOI: 10.1080/00397919808006862
- [51] Bombardelli E. Eur. Pat. Appl., EP870761/98 (Chem. Abstr. 1998, 129, 290269)
- [52] Lee SH, Park S-K, Kim J-M, Kim M-H, Kim KH, Chum KW, Cho KH, Youn J-Y, Namgoong SK. New synthetic thiocolchicine derivatives as low-toxic anticancer agents. *Archiv der Pharmazie—Chemistry in Life Sciences*. 2005;**388**:582-589. DOI: 10.1002/ardp.200500148
- [53] Nakagawa-Gotto K, Chen C, Hamel E, Wu C-C, Bastow KF, Brossi A, Lee KH. Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives. *Bioorganic & Medicinal Chemistry Letters*. 2005;**15**:235-238. DOI: 10.1016/j.bmcl.2004.07.098
- [54] Guan J, Zhu X-K, Tachibana Y, Bastow KF, Brossi A, Hamel E, Lee KH. Antitumor agents. 185. Synthesis and biological evaluation of tridemetoxythiocolchicine analogues as novel topoisomerase II inhibitors. *Journal of Medicinal Chemistry*. 1998;**41**:1956-1961. DOI: 10.1021/jm980007f
- [55] Kozaka T, Nakagawa-Goto K, Shi Q, Lai CY, Hamel E, Bastow KF, Brossi A, Lee K-H. Antitumor agents 273. Design and synthesis of N-alkyl-thiocolchicinoids as potential antitumor agent. *Bioorganic & Medicinal Chemistry Letters*. 2010;**20**:4091-4094. DOI: 10.1016/j.bmcl.2010.05.081
- [56] Banwell M, Peters SC, Greenwood RJ, Mackay MF, Hamel E, Lin CM. Semisyntheses, X-ray crystal structures and tubulin-binding properties of 7-oxodeacetamidocolchicine and 7-oxodeacetamidoisocolchicine. *Australian Journal of Chemistry*. 1992;**45**(10):1577-1588. DOI: 10.1071/CH9921577
- [57] Passarella D, Giardini A, Peretto B, Fontana G, Sacchetti A, Silvani A, Ronchi C, Cappelletti G, Cartelli D, Borlak J, Danielli B. Inhibitors of tubulin polymerization: Synthesis and biological evaluation of hybrids of vindofine, anhydrovinblastine and vinorelbine with thiocolchicine, podophylotoxin and baccatin III. *Bioorganic & Medicinal Chemistry*. 2008;**16**:6269-6285. DOI: 10.1016/j.bmc.2008.04.025

- [58] Capelletti G, Cartelli D, Peretto B, Ventura M, Riccioli M, Colombo F, Snaith JS, Borrelli S, Passarella D. Tubulin-guided dynamic combinatorial library of thiocolchicine-podophyllotoxin conjugates. *Tetrahedron*. 2011;**67**:7354-7357. DOI: 10.1016/j.tet.2011.07.038
- [59] Sun L, McPhail AT, Hamel E, Lin CM, Hastie S, Chang JJ, Lee K-H. Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogues 5,6-dihydro-6-(S)-(acyloxy)- and 5,6-dihydro-6-(S)[(aroyloxy)methyl]-1,2,3-trimethoxy-9-(methylthio)8H-cyclohepta[a]naphthalen-8-ones as novel cytotoxic and antimitotic agents. *Journal of Medicinal Chemistry*. 1993;**36**:544-551. DOI: 10.1021/jm00057a004
- [60] Schonharting M, Mende G, Siebert G. Hoppe-Seyler's. *Zeitschrift für Physiologische Chemie*. 1974;**355**:1991
- [61] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJJ. Colchicine biotransformation by human liver microsomes: Identification of cyp3a4 as the major isoform responsible for colchicine demethylation. *Biochemical Pharmacology*. 1997;**53**(1):111-116. DOI: 10.1016/S0006-2952(96)00693-4
- [62] Pal D, Mahapatra P, Manna T, Chakrabati P, Bhattacharyya B, Banerje A, Basu G, Roy S. Conformational properties of α -tubulin tail peptide: Implication for tail-body interaction. *Biochemistry*. 2001;**40**:15512-15519. DOI: 10.1021/bi015677t
- [63] Sułowska A, Maciążek-Jurczyk M, Bojko B, Równicka J, Zubik-Skupień I, Temba E, Pentak D, Sułkowski WW. Competitive binding of phenylbutazone and colchicine to serum albumin in multidrug therapy: A spectroscopic study. *Journal of Molecular Structure*. 2008;**881**:97-106. DOI: 10.1016/j.molstruc.2007.09.001
- [64] Hu YJ, Liu Y, Zhao RM, Qu SS. Interaction of colchicine with human serum albumin investigated by spectroscopic methods. *International Journal of Biological Macromolecules*. 2005;**37**:122-126. DOI: 10.1016/j.ijbiomac.2005.09.007
- [65] Sharma S, Poliks B, Chiauzzi C, Ravindra R, Blanden AR, Bane S. Characterization of the colchicine binding site on avian tubulin isotype β VI. *Biochemistry*. 2010;**49**:2932-2942. DOI: 10.1021/bi100159p
- [66] Shi Q, Verdier-Pinard P, Brossi A, Hamel E, Lee KH. Antitumor agents-CLXXV. Antitubulin action of (+)-thiocolchicine prepared by partial synthesis. *Bioorganic & Medicinal Chemistry*. 1997;**5**(12):2277-2282. DOI: 10.1016/S0968-0896(97)00171-5
- [67] Ferri P, Bruno C, Cecchini T, Ciaroni S, Ambrogini P, Guidi L, Cuppini R, Bombardelli E, Morazzoni P, Riva A, Del Grande P. Effects of thiocolchicine on axonal cytoskeleton of rat peroneus nerve. *Experimental and Toxicologic Pathology*. 2002;**54**:211-216. DOI: 10.1078/0940-2993-00249
- [68] Toscano IL, Rezende MV, Mello LF, Pires L, Paulillo D, Glina S. A prospective, randomized, single-blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's disease: A pilot study. *International Brazilian Journal of Urology*. 2016;**42**(5):1005-1009. DOI: 10.1590/S1677-5538.IBJU.2015.0598

- [69] Batrusik D, Tomanek B, Lattová E, Perreault H, Tuszyński J, Fallone G. Derivatives of thiocolchicine and its applications to CEM cells treatment using ^{19}F magnetic resonance *ex vivo*. *Bioorganic Chemistry*. 2010;**38**:1-6. DOI: 10.1016/j.bioorg.2009.10.002
- [70] Passarella D, Peretto B, Blasco y Yepes R, Cappelletti G, Cartelli D, Ronchi C, Snaith J, Fontana G, Danieli B, Borlak J. Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates. *European Journal of Medicinal Chemistry*. 2010;**45**:219-226. DOI: 10.1016/j.ejmech.2009.09.047
- [71] Alali FQ, Gharaibeh AA, Ghawanmeh A, Tawaha K, Qandil A, Burgess JP, Sy A, Nakanishi Y, Kroll DJ, Oberlies NH. Colchicinoids from *Colchicum crocifolium* Boiss. (*Colchicaceae*). *Natural Product Research*. 2010;**24**(2):152-159. DOI: 10.1080/14786410.902941097
- [72] Gelmi ML, Motadelli S, Pocar D, Riva A, Bombardelli E, de Vincenzo R, Scambia G. *N*-deacetyl-*N*-aminoacetylthiocolchicine derivatives: Synthesis and biological evaluation on MDR-positive and MDR-negative human cancer cell lines. *Journal of Medicinal Chemistry*. 1999;**42**:5272-5276. DOI: 10.1021/jm981134e
- [73] Baker MA, Gray BD, Ohlsson-Wilhelm BM, Varpenter DC, Muirhead KA. Zyn-linked colchicines: controlled-release lipophilic prodrugs with enhanced antitumor activity. *Journal of Controlled Release*. 1996;**40**(1-2):89-100. DOI: 10.1016/0168-3659(95)00177-8
- [74] Chabin RM, Feliciano F, Hastie SB. Effects of tubulin binding and self-association on the near-ultraviolet circular dichroic spectra of colchicine and analogues. *Biochemistry*. 1990;**29**(7):1869-1875. DOI: 10.1021/bi00459a029
- [75] Brossi A. Bioactive alkaloids. 4. Results of recent investigation with colchicine and physostigmine. *Journal of Medicinal Chemistry*. 1990;**33**:2311-2319. DOI: 10.1021/jm00171a001
- [76] Brossi A, Herman JC, Chrzanowska M, Wolff J, Hamel E, Lin CM, Quin F, Suffness M, Silverton J. Colchicine and its analogues: Recent findings. *Medicinal Research Reviews*. 1988;**8**(1):77-94. DOI: 10.1002/med.2610080105
- [77] Gohar MA, Makkawi M. The antibacterial action of colchicine and colchicine. *The Journal of Pharmacy and Pharmacology*. 1951;**3**(1):415-419. DOI: 10.1111/j.2042-7158.1951.tb13083.x
- [78] Kim SK, Cho SM, Kim H, Seok H, Kim SO, Kwon TK, Chang JS. The colchicine derivative CT20126 shows a novel microtubule-modulating activity with apoptosis. *Experimental & Molecular Medicine*. 2013;**45**:e19. DOI: 10.1038/emm.2013.38
- [79] Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MRL, Chaplin DJ, Hill SA. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. *Cancer Research*. 2002;**62**(15):7247-7253
- [80] Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, Scambia G. Thiocolchicine dimers: A novel class of topoisomerase-I inhibitors. *Biochemical Pharmacology*. 2005;**69**:113-121. DOI: 10.1016/j.bcp.2004.09.004

- [81] Bombuwala K, Kinstle T, Popik V, O Uppal S, Olesen JB, Viña J, Heckman CA. Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. *Beilstein Journal of Organic Chemistry*. 2006;**2**:13-21. DOI: 10.1186/1860-5397-2-13
- [82] Imazio M, Brucato A, Cemin R. A randomized trial for acute pericarditis. *New England Journal of Medicine*. 2013;**369**:1522-1528. DOI: 10.1056/NEJMoa1208536
- [83] Terkeltaub RA, Furst DE, Bennet K, kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled parallel-group, dose-comparison colchicine study. *Arthritis and Rheumatism*. 2010;**62**:1060-1068. DOI: 10.1002/art.27327
- [84] Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. *European Journal of Internal Medicine*. 2010;**21**:503-508. DOI: 10.1016/j.ejim.2010.09.010
- [85] Gervasi M, Sisti D, Benelli P, Fernández-Peña E, Calcabini C, Rocchi MBL, Lanata L, Bagnasco M, Tonti A, Viberto S, Sestili P. The effect of topical thiocolchicoside in preventing and reducing the increase of muscle tone, stiffness and soreness. *Medicine*. 2017;**96**(30):1-8. DOI: 10.1097/MD.00000000000007659
- [86] Abolhasani H, Zarghi A, Hamzeh-Mivehroud M, Alizadeh AA, Shahbazi J, Mojarad SD. *In-silico* investigation of tubulin binding modes of a series of novel antiproliferative spiroisoxazoline compounds using docking studies. *Iranian Journal of Pharmaceutical Research*. 2015;**14**(1):141-147
- [87] Hu MJ, Zhang B, Yang HK, Liu Y, Chen YR, Ma TZ, Lu L, You WW, Zhao PL. Design, synthesis and molecular docking studies of novel indole-pyrimidine hybrids as tubulin polymerization inhibitors. *Chemical Biology & Drug Design*. 2015;**86**(6):1491-1500. DOI: 10.1111/cbdd.12616
- [88] Kumbhar BV, Borogaon A, Panda D, Kunwar A. Exploring the origin of differential binding affinities of human tubulin isotypes $\alpha\beta$ II, $\alpha\beta$ III and $\alpha\beta$ IV for DAMA-colchicine using homology modelling, molecular docking and molecular dynamics simulations. *PLoS One*. 2016;**11**(5):e0156048. DOI: 10.1371/journal.pone.0156048
- [89] Li H, Liu T, Xuan H, Fang S, Zhao C. A combination of pharmacophore modeling, virtual screening, and molecular docking studies for a diverse set of colchicine site inhibitors. *Medicinal Chemistry Research*. 2014;**23**(11):4713-4723. DOI: 10.1007/s00044-014-1028-7
- [90] Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. *Journal of Medicinal Chemistry*. 2005;**48**(19):6107-6116. DOI: 10.1021/jm050502t